Designer Gene Therapy Using an Escherichia coli Purine Nucleoside Phosphorylase/Prodrug System

Chemistry and Biology

Volumn 10, Issue 12, 2003, Pages 1173-1181

  Bennett, Eric M ^a   Anand, Ruchi ^a   Allan, Paula W ^b   Hassan, Abdalla E A ^b   Hong, Jeong S ^c   Levasseur, Dana N ^e   McPherson, David T ^c   Parker, William B ^b   Secrist III, John A ^b   Sorscher, Eric J ^d   Townes, Tim M ^e   Waud, William R ^b   Ealick, Steven E ^a  

^a Department of Obstetrics Gynecology   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; ESCHERICHIA COLI;

EID: 0347599048     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2003.11.008     Document Type: Article

References (49)

1. Xu G., McLeod H.L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 7:2001;3313-3324.
2. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
3. Conference briefings. (1999). Hum. Gene Ther. 10, 3065-3123.
4. Beck C., Cayeux S., Lupton S.D., Dorken B., Blankenstein T. The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum. Gene Ther. 6:1995;1525-1530.
5. Dennig, C.N., and Pitts, J.D. (1997). Presented at Mol. Cell. Biol. of Gene Therapy, Snowbird, UT, Keystone Symposia.
6. Mesnil, M., and Yamasaki, H. (1997). Presented at Mol. Cell. Biol. of Gene Therapy, Snowbird, UT, Keystone Symposia.
7. Sacco M.G., Benedetti S., Duflotdancer A., Mesnil M., Bagnasco L., Strina D., Fasolo V., Villa A., Macchi P., Faranda S.et al. Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer 'in vivo.'. Gene Ther. 3:1996;1151-1156.
8. Wygoda M.R., Wilson M.R., Davis M.A., Trosko J.E., Rehemtulla A., Lawrence T.S. Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells. the Good Samaritan effect Cancer Res. 57:1997;1699-1703.
9. Scrutton N.S., Berry A., Perham R.N. Redesign of the coenzyme specificity of a dehydrogenase by protein engineering. Nature. 343:1990;38-43.
10. Clarke A.R. From analysis to synthesis. new ligand binding sites on the lactate dehydrogenase framework Part II. Trends Biochem. Sci. 14:1989;145-148.
11. Reeves C.D., Murli S., Ashley G.W., Piagentini M., Hutchinson C.R., McDaniel R. Alteration of the substrate specificity of a modular polyketide synthase acyltransferase domain through site-specific mutations. Biochemistry. 40:2001;15464-15470.
12. Lin Q., Jiang F., Schultz P.G., Gray N.S. Design of allele-specific protein methyltransferase inhibitors. J. Am. Chem. Soc. 123:2001;11608-11613.
13. Meng M., Lee C., Bagdasarian M., Zeikus J.G. Switching substrate preference of thermophilic xylose isomerase from D-xylose to D-glucose by redesigning the substrate binding pocket. Proc. Natl. Acad. Sci. USA. 88:1991;4015-4019.
14. Corbier C., Clermont S., Billard P., Skarzynski T., Branlant C., Wonacott A., Branlant G. Probing the coenzyme specificity of glyceraldehyde-3-phosphate dehydrogenases by site-directed mutagenesis. Biochemistry. 29:1990;7101-7106.
15. Koh J.T. Engineering selectivity and discrimination into ligand-receptor interfaces. Chem. Biol. 9:2002;17-23.
16. Penning T.M., Jez J.M. Enzyme redesign. Chem. Rev. 101:2001;3027-3046.
17. Agarwal K.C., Agarwal R.P., Stoeckler J.D., Parks R.E. Jr. Purine nucleoside phosphorylase. Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and species. Biochemistry. 14:1975;79-84.
18. Krenitsky T.A. Purine nucleoside phosphorylase. kinetics, mechanism, and specificity Mol. Pharmacol. 3:1967;526-536.
19. Gadi V.K., Alexander S.D., Kudlow J.E., Allan P., Parker W.B., Sorscher E.J. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 7:2000;1738-1743.
20. Martiniello-Wilks R., Garcia-Aragon J., Daja M.M., Russell P., Both G.W., Molloy P.L., Lockett L.J., Russell P.J. In vivo gene therapy for prostate cancer. preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors Hum. Gene Ther. 9:1998;1617-1626.
21. Mohr L., Shankara S., Yoon S.K., Krohne T.U., Geissler M., Roberts B., Blum H.E., Wands J.R. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology. 31:2000;606-614.
22. Parker W.B., King S.A., Allan P.W., Bennett L.L., Secrist J.A. III, Montgomery J.A., Gilbert K.S., Waud W.R., Wells A.H., Gillespie G.Y.et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther. 8:1997;1637-1644.
23. Parker W.B., Allan P.W., Hassan A.E.A., Secrist J.A. III, Sorscher E.J., Waud W.R. Anti-tumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express E. coli purine nucleoside phosphorylase. Cancer Gene Ther. 10:2003;23-29.
24. Voeks D., Martiniello-Wilks R., Madden V., Smith K., Bennetts E., Both G.W., Russell P.J. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 9:2002;759-768.
25. Hughes B.W., King S.A., Allan P.W., Parker W.B., Sorscher E.J. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J. Biol. Chem. 273:1998;2322-2328.
26. Sorscher E.J., Peng S., Bebok Z., Allan P.W., Bennett L.L.J., Parker W.B. Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines. Gene Ther. 1:1994;233-238.
27. Coates M.E. The Germ-Free Animal in Research. 1968;Academic Press, London.
28. Pleasants J.P. Gnotobiotics. Melby E.C., Altman N.H. Handbook of Laboratory Animal Science. 1974;115-174 CRC Press, Cleveland, OH.
29. Trexler P.C. Gnotobiotics. Foster H.L., Small J.D., Fox J.G. The Mouse in Biomedical Research. 1983;Academic Press, New York.
30. Mao C., Cook W.J., Zhou M., Koszalka G.W., Krenitsky T.A., Ealick S.E. The crystal structure of Escherichia coli purine nucleoside phosphorylase. a comparison with the human enzyme reveals a conserved topology Structure. 5:1997;1373-1383.
31. Secrist J.A. III, Parker W.B., Allan P.W., Bennett L.L., Waud W.R., Truss J.W., Fowler A.T., Montgomery J.A., Ealick S.E., Wells A.H.et al. Gene therapy of cancer. activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase Nucleosides Nucleotides. 18:1999;745-757.
32. Reist E.J., Goodman L., Spencer R.R., Baker B.R. Potential anticancer agents. IV. Synthesis of nucleosides derived from 6-deoxy-D-allofuranose. J. Am. Chem. Soc. 80:1958;3962-3966.
33. Reist E.J., Goodman L., Baker B.R. Potential anticancer agents. VIII. Synthesis of nucleosides derived from L-talofuranose. J. Am. Chem. Soc. 80:1958;5775-5779.
34. Nutt R.F., Walton E. Branched-chain sugar nucleosides. II. 5′,5′-Di-C-methyladenosine. J. Med. Chem. 11:1968;151-153.
35. Lerner L.M., Kohn B.D., Kohn P. Preparation of nucleosides via isopropylidene sugar derivatives. 3. Synthesis of 9-beta-D-gulofuranosyladenine and 9-alpha-L-lyxofuranosyladenine. J. Org. Chem. 33:1968;1780-1783.
36. Wnuk S.F., Yuan C.S., Borchardt R.T., Balzarini J., De Clercq E., Robins M.J. Anticancer and antiviral effects and inactivation of S-adenosyl-L- homocysteine hydrolase with 5′-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues. J. Med. Chem. 40:1997;1608-1618.
37. Hassan A.E.A., Abou-Elkair R.A.I., Montgomery J.A., Secrist J.A. III. Convenient syntheses of 6-methylpurine and related nucleosides. Nucleosides Nucleotides Nucleic Acids. 19:2000;1123-1134.
38. Qiu D., Shenkin P.S., Hollinger F.P., Still W.C. The GB/SA continuum model for solvation. A fast analytical method for the calculation of approximate born radii. J. Phys. Chem. A. 101:1997;3005-3014.
39. Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., Still W.C. MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11:1990;460-467.
40. 80 and flexible docking of 9-deazaguanine inhibitors into PNP J. Comput. Chem. 20:1999;1671-1684.
41. Chang G., Guida W.C., Still W.C. An internal coordinate Monte Carlo method for searching conformational space. J. Am. Chem. Soc. 111:1989;4379-4386.
42. Leslie A.G.W. MOSFLM Version 5.40. 1997;MRC Laboratory of Molecular Biology, Cambridge, UK.
43. Evans P.R. SCALA Version 3.3. 1993;MRC Laboratory of Molecular Biology, Cambridge, UK.
44. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography & NMR system. A new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921.
45. Jones T.A., Zou J.-Y., Cowan S.W., Kjeldgaard M. Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
46. Trono D. LV'S Kitchen. Trono Lab. www.tronolab.unige.ch/lvkitchen.html: 2002.
47. Dykes D.J., Abbott B.J., Mayo J.G., Harrison S.D.J., Laster W.R., Simpson-Herren L., Griswold D.P.J. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib. Oncol. 42:1992;1-22.
48. Kraulis P.J. Molscript. a program to produce both detailed and schematic plots of protein structures J. Appl. Crystallogr. 24:1991;946-950.
49. Merritt E.A., Bacon D.J. Raster3D. photorealistic molecular graphics Methods Enzymol. 277:1997;505-524.